What is a urinary tract infection?

A UTI is a bacterial infection of any part of the urinary tract — kidneys (pyelonephritis), bladder (cystitis), urethra (urethritis) or prostate (prostatitis in men). The most common form is cystitis — causing dysuria (burning on urination), frequency, urgency, suprapubic pain and sometimes haematuria. Most UTIs are uncomplicated (healthy premenopausal women without structural abnormalities); complicated UTIs include those in pregnancy, men, elderly, catheterised patients or those with renal abnormalities.

Why are women so much more susceptible?

Women's urethra is approximately 4cm long (vs 20cm in men) — a short distance from the external urethral meatus to the bladder, making bacteria readily accessible. The female urethra is close to the vagina and anus — with E. coli from the rectal flora able to reach the urethra easily. Sexual intercourse introduces bacteria into the urethra ("honeymoon cystitis"). Hormonal changes (menopause, with reduced vaginal lactobacilli and elevated vaginal pH) increase risk. Pregnancy causes urinary stasis from uterine compression. All these factors result in women having approximately 30x higher UTI incidence than men.

What is the treatment for a UTI?

Treatment depends on severity and patient factors: Uncomplicated cystitis (otherwise healthy women): 3-7 days of nitrofurantoin (5 days), fosfomycin (single dose), pivmecillinam or trimethoprim — guided by local resistance patterns; fluoroquinolones and co-amoxiclav are NOT first-line (to preserve them and because resistance/broad-spectrum effects). Pyelonephritis: 7-14 days — ciprofloxacin or co-amoxiclav (adjusted for culture results); IV treatment (ceftriaxone, gentamicin) for severe cases. ESBL infection: ertapenem or meropenem; may consider fosfomycin or nitrofurantoin for lower UTI if susceptible.

Why is antibiotic resistance making UTIs harder to treat?

Rising resistance is the defining treatment challenge for UTIs. Globally: fluoroquinolone resistance in E. coli has reached 20-30% in many countries (eliminating these drugs as reliable first-line agents for UTI); trimethoprim resistance exceeds 20% in many regions; ESBL-producing E. coli (resistant to all cephalosporins and most penicillins) now cause 10-20% of UTIs in some settings — often requiring IV carbapenems. WHO has designated ESBL-producing Enterobacteriaceae as a critical priority for new antibiotic development.

What is recurrent UTI and how is it managed?

Recurrent UTI (≥2 episodes in 6 months or ≥3 in 12 months) affects approximately 25% of women who have had a UTI. Most recurrences are reinfections (new bacteria) not relapse of the same infection. Management options: antibiotic prophylaxis (continuous low-dose, or post-coital — very effective but carries resistance risk with long-term use); patient-initiated self-treatment (patient diagnoses own recurrence and starts pre-prescribed antibiotic — as effective as prophylaxis, less antibiotic exposure); non-antibiotic: vaginal oestrogen (postmenopausal women — reduces risk approximately 50%), D-mannose, methenamine hippurate, Lactobacillus probiotics.

Can UTIs be prevented?

Evidence-based prevention: adequate fluid intake (dilutes uropathogens); voiding after intercourse; wiping front to back; vaginal oestrogen for postmenopausal women (most effective non-antibiotic intervention). For catheter-associated UTI: catheter-free if possible; strict aseptic technique; daily catheter review; closed drainage systems. Cranberry products: have evidence for modest UTI prevention in women (approximately 26% relative risk reduction in RCT meta-analyses); mechanism — proanthocyanidins reduce E. coli adhesion. D-mannose: emerging non-antibiotic option.

How does UTI relate to the AMR agenda?

UTIs are the single most common indication for antibiotic prescribing in community settings globally — making them central to the AMR crisis. Overdiagnosis (treating asymptomatic bacteriuria — which is common in older adults — unnecessarily); overconsumption of broad-spectrum antibiotics (fluoroquinolones, co-amoxiclav); and resistance selection in the gut microbiome all drive the UTI-AMR relationship. UTI antibiotic stewardship — including dipstick testing before prescribing, deferred prescribing for mild UTI, and using narrow-spectrum first-line agents — is a key WHO AMR action priority.

How does GMJ News cover UTIs?

GMJ News covers WHO UTI burden data, ESBL resistance trends, antimicrobial stewardship, recurrent UTI management, CAUTI prevention and non-antibiotic approaches. UTIs and AMR are directly relevant to PHIG's hospital infection control programme, Georgian antibiotic stewardship agenda and the Georgian Medical Journal.

Home › Topics › Urinary Tract Infections

Urinary Tract Infections

GMJ News knowledge hub · last reviewed September 2026 · Georgian Medical Journal

Summary Statistics Glossary GMJ news FAQ Documents Organizations Research

Urinary tract infections (UTIs) are the most common bacterial infections in community and healthcare settings globally — causing an estimated 400 million symptomatic episodes per year, with women bearing approximately 30-fold greater burden than men due to anatomical, hormonal and microbiome differences (WHO). Escherichia coli causes approximately 80% of uncomplicated community UTIs. Rising antimicrobial resistance — particularly ESBL-producing Enterobacteriaceae — is dramatically complicating UTI treatment globally, reducing first-line antibiotic options and increasing reliance on carbapenems for multidrug-resistant uropathogens. Recurrent UTIs (≥2 episodes in 6 months) affect approximately 25% of women who have had a first episode.

Key messages

400 million episodes/year — most common bacterial infection

Urinary tract infections cause approximately 400 million symptomatic episodes per year globally — the most common bacterial infection in community settings worldwide, accounting for 8-10 million physician visits per year in the US alone (WHO).

Women bear 30x higher burden

Women are approximately 30 times more likely than men to develop a UTI — due to shorter urethra, proximity to anal flora, and hormonal changes affecting vaginal microbiome. Approximately 50% of women have at least one UTI in their lifetime; 25% develop recurrent UTI.

E. coli causes 80% of uncomplicated UTIs

Escherichia coli causes approximately 80% of community-acquired uncomplicated UTIs. Klebsiella, Proteus, Enterococcus and Staphylococcus saprophyticus are other common uropathogens.

AMR is the defining treatment challenge

Rising antimicrobial resistance — particularly ESBL (extended-spectrum beta-lactamase) producing Enterobacteriaceae — is dramatically limiting first-line treatment options globally, reducing the effectiveness of trimethoprim, fluoroquinolones and nitrofurantoin in many regions, and increasing reliance on IV carbapenems for severe UTI.

Complicated vs uncomplicated UTI

Uncomplicated UTI (healthy premenopausal women with no structural abnormalities): short-course antibiotics (3-7 days). Complicated UTI (pregnancy, men, elderly, catheter-associated, structural abnormalities, immunosuppression): longer courses and broader-spectrum antibiotics; investigation needed.

Recurrent UTI management

Recurrent UTI (≥2 in 6 months or ≥3 in 12 months): low-dose antibiotic prophylaxis; post-coital single-dose prophylaxis; patient-initiated self-treatment; or non-antibiotic approaches (vaginal oestrogen in postmenopausal women; D-mannose; methenamine hippurate).

Key statistics

~400M

symptomatic UTI episodes/year globally

WHO

30x

higher UTI burden in women vs men

WHO

50%

of women have at least 1 UTI in lifetime

WHO/Cochrane

80%

of uncomplicated UTIs caused by E. coli

WHO/ESCMID

25%

of women develop recurrent UTI

WHO

Rising

ESBL UTI resistance dramatically limiting first-line options

WHO/ECDC

UTI resistance trends — % of E. coli isolates resistant to key antibiotics (ECDC/WHO)

Source: ECDC EARS-Net and WHO data. Fluoroquinolone and trimethoprim resistance now exceeds 20-30% in many regions.

Glossary of key terms

ESBL (Extended-spectrum beta-lactamase)
WHO/ESCMIDEnzymes produced by E. coli, Klebsiella and other Enterobacteriaceae — hydrolyse most beta-lactam antibiotics including 3rd generation cephalosporins (ceftriaxone, cefotaxime) and all penicillins. ESBL-producing organisms are resistant to most common UTI antibiotics — often only treatable with carbapenems (IV). Worldwide prevalence rising rapidly, especially in South and Southeast Asia.

Cystitis vs pyelonephritis
WHOCystitis: lower UTI — infection of the bladder. Symptoms: dysuria (painful urination), frequency, urgency, haematuria (blood in urine), suprapubic pain. No fever. Treated with 3-7 days of antibiotics. Pyelonephritis: upper UTI — infection of the kidneys. Symptoms: fever (>38°C), rigors, flank pain, nausea/vomiting ± cystitis symptoms. Requires 7-14 day treatment; IV antibiotics for severe cases.

Recurrent UTI (rUTI)
ESCMID/EAUDefined as ≥2 UTIs in 6 months or ≥3 UTIs in 12 months. Management options: continuous low-dose antibiotic prophylaxis (trimethoprim, nitrofurantoin, cefalexin — taken daily at low dose, reduces rUTI by approximately 60-85%); post-coital prophylaxis (single-dose after intercourse — for coital-related rUTI); patient-initiated self-treatment; vaginal oestrogen (reduces rUTI by approximately 50% in postmenopausal women); D-mannose (preliminary evidence).

Catheter-associated UTI (CAUTI)
WHO/CDCThe most common healthcare-associated infection globally — urinary catheters in hospitals and long-term care are the primary risk factor. Every day of catheterisation increases UTI risk by approximately 5%. Prevention: removing catheters as soon as clinically possible; sterile insertion technique; closed drainage systems.

D-mannose
WHO/EAUA naturally occurring sugar that may prevent E. coli attachment to uroepithelial cells (which express mannose-binding proteins that E. coli use for adhesion). Evidence: one RCT showed D-mannose reduced recurrent UTI similarly to trimethoprim prophylaxis. Non-antibiotic approach — safe, no resistance risk.

Methenamine hippurate
ESCMID/EAUA urinary antiseptic (converts to formaldehyde in acidic urine) — used for recurrent UTI prevention in women with no renal tract abnormality. One RCT showed efficacy equivalent to antibiotic prophylaxis. WHO EML. Resistance-proof mechanism. Emerging preference for antibiotic-sparing rUTI prevention.